M. Mirza, Sudarshan Sharma, Jørn Herrstedt, M. Shahin, David Cibula, E. Fleming, F. Raspagliesi, J. Buscema, L. Hanker, Robert L Coleman, I. Boere, K. Schneider, L. Gilbert, B. Slomovitz, M. Teneriello, M. Powell, Srimoyee Ghosh, S. Stevens, K. Ring, A. Stuckey
{"title":"625 多斯他利单抗+化疗治疗原发性晚期或复发性子宫内膜癌:ENGOT-EN6-NSGO/GOG-3031/RUBY试验中按分子分类的无进展生存期和总生存期结果分析","authors":"M. Mirza, Sudarshan Sharma, Jørn Herrstedt, M. Shahin, David Cibula, E. Fleming, F. Raspagliesi, J. Buscema, L. Hanker, Robert L Coleman, I. Boere, K. Schneider, L. Gilbert, B. Slomovitz, M. Teneriello, M. Powell, Srimoyee Ghosh, S. Stevens, K. Ring, A. Stuckey","doi":"10.1136/ijgc-2024-esgo.32","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"107 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"625 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"M. Mirza, Sudarshan Sharma, Jørn Herrstedt, M. Shahin, David Cibula, E. Fleming, F. Raspagliesi, J. Buscema, L. Hanker, Robert L Coleman, I. Boere, K. Schneider, L. Gilbert, B. Slomovitz, M. Teneriello, M. Powell, Srimoyee Ghosh, S. Stevens, K. Ring, A. Stuckey\",\"doi\":\"10.1136/ijgc-2024-esgo.32\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"107 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.32\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
625 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial